CRISPR/Cas9 mediated GPRC6A deficient PC-3 xenograft cells showed reduced tumor growth and osteocalcin-associated progression of prostate cancer as compared to GPRC6A expressing PC-3 cells (Ye et al., 2017). Here, GPRC6A is linked to prostate carcinoma.